

3763

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Stephen R. Ash

Serial No.: 09/763,666

Filed: February 23, 2001

METHOD OF ENHANCING CATHETER
PATENCY USING A CITRATE SALT
CATHETER LOCK SOLUTION

Before the Examiner

Group Art Unit

August 10, 2001

INFORMATION DISCLOSURE STATEMENTHonorable Commissioner for Patents
Washington, DC 20231

Sir:

Pursuant to the duty of disclosure embodied in 37 CFR §1.56, Applicants wish to bring to the attention of the Examiner the following patents, publications and/or other information:

1. U.S. Patent No. 4,364,929 to Sasmor et al. issued December 21, 1982
2. U.S. Patent No. 4,677,143 to Laurin et al. issued June 30, 1987.
3. U.S. Patent No. 5,032,615 to Ward et al. issued July 16, 1991.
4. U.S. Patent No. 5,665,061 to Antwiler issued September 9, 1997.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Honorable Commissioner for Patents, Washington, D.C. 20231 on August 10, 2001.

GREGORY B. COY

Name of Registered Representative

Signature

August 10, 2001

Date of Signature

INFORMATION DISCLOSURE STATEMENT

Serial No. 09/763,666

Attorney Docket No. 11020-55

Page 1 of 3

RECEIVED
AUG 21 2001
TECHNOLOGY CENTER 3700

5. U.S. Patent No. 5,709,993 to Buturovic-Ponikvar issued January 20, 1998.
6. U.S. Patent No. 5,843,016 to Lugnani et al. issued December 1, 1998.
7. Olinger GN, Hottenrott C, Mulder DG, Maloney JV, Miller J, Patterson RW, Sullivan SF, Buckberg GD. Acute clinical hypocalcemic myocardial depression during rapid blood transfusion and postoperative hemodialysis. *Journal of Thoracic and Cardiovascular Surgery* 72: 503-511, October 1976.
8. Dzik WH, Kirkley SP. Citrate toxicity during massive blood transfusion. *Transfusion Medicine Reviews* 2:76-94, June 1988.
9. Kelleher SP, Schulman G. Severe metabolic alkalosis complicating regional citrate hemodialysis. *Am J Kidney Dis* 9: 235-236, March 1987.
10. Lohr JW, Slusher S, Diederich D. Safety of regional citrate hemodialysis in acute renal failure. *Am J Kidney Dis* 8:104-107, February 1989.
11. Leray-Moragues H, Bose LY, Canaud B. Gentamicin/sodium citrate mixture: a promising antibiotic lock for preventing catheter related infections. Lapeyronie Univerity Hospital, Montpellier, France, date unknown.
12. Von Brecht JH, Flanigan MJ, Freeman RM, Lim VS. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. *Am J Kidney Dis* 8:196-201, September 1986.
13. Purchase L, Gault MH. Hemodialysis with a Permcath kept open with streptokinase and later citrate in a heparin-sensitive patient. *Nephron* 48:119-120, 1991.
14. Flanigan MJ, Pillsbury L, Sadewasser G, Lim VS. Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. *Am J Kidney Dis* 27:519-524, April 1996.
15. Sodemann K, Lubrich-Birkner I, Berger O, Baumert J, Feldmer B, Von Hodenberg E. Gentamicin/sodium-citrate mixture as antibiotic-lock technique for salvage and prevention of catheter-related infections – A four year trial. *J Am Soc Nephrol* 8:173A, 1997.
16. Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P. Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. *Artif Organs* 22:945-946, 1998.
17. Branson PK, McCoy RA, Phillips BA, Clifton GD. Efficacy of 1.4 percent sodium citrate in maintaining arterial catheter patency in patients in a medical ICU. *Chest* 103:882-885, March 1993.

INFORMATION DISCLOSURE STATEMENT

Serial No. 09/763,666

Attorney Docket No. 11020-55

Page 2 of 3


This information has not been previously submitted in this application, and has not been cited previously by the Examiner. Copies of cited items are enclosed in accordance with 37 CFR §1.98.

The identified information, taken alone or in combination with other art, provides information relating to the subject matter of the invention, however, the filing of this Information Disclosure Statement shall not be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in §1.56(b).

This Statement is being submitted prior to the mailing of any Office Action on the merits. It is believed that no fee is required for consideration of the submitted items. Should any fee be required, however, please charge such fee to Deposit Account No. 23-3030, but not to include the payment of any issue fees.

Respectfully submitted

By: _____


Gregory B. Coy
Reg. No. 40,967
Woodard, Emhardt, Naughton,
Moriarty & McNett
Bank One Center/Tower
111 Monument Circle, Suite 3700
Indianapolis, Indiana 46204-5137
(317) 634-3456